# A Study of Azenosertib (ZN-c3) in Women With Recurrent or Persistent Uterine Serous Carcinoma

> **NCT04814108** · PHASE2 · COMPLETED · sponsor: **K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc** · enrollment: 92 (actual)

## Conditions studied

- Uterine Serous Carcinoma

## Interventions

- **DRUG:** Azenosertib

## Key facts

- **NCT ID:** NCT04814108
- **Lead sponsor:** K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-28
- **Primary completion:** 2025-10-22
- **Final completion:** 2025-10-22
- **Target enrollment:** 92 (ACTUAL)
- **Last updated:** 2026-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04814108

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04814108, "A Study of Azenosertib (ZN-c3) in Women With Recurrent or Persistent Uterine Serous Carcinoma". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT04814108. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*